• Imugene receives A$20 million from issuance of senior, unsecured, zero-coupon convertible notes
• Funding to advance Imugene's immuno-oncology clinical trial pipeline, including azer-cel, onCARlytics, and VAXINIA programs
• Convertible notes have a five-year maturity with no interest costs and potential semi-annual conversion to ordinary shares

Imugene Limited, a clinical-stage immuno-oncology company, has announced that it has received A$20 million from the issuance of senior, unsecured, zero-coupon convertible notes to CVI Investments, Inc. This funding represents the first tranche of a total A$46 million capital raising announced on 23 December 2024, comprising convertible notes and associated unlisted warrants. The proceeds from this initial tranche will be directed toward advancing Imugene's immuno-oncology clinical trial pipeline, including azer-cel, onCARlytics, and VAXINIA programs. The convertible notes have a five-year maturity and provide significant flexibility for Imugene, with no interest costs and potential semi-annual conversion to ordinary shares at a premium to the Company's market price. Imugene is a clinical-stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. The company's pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers, as well as multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours.